Evidence map›Paper›PMID 40192583›Full record

ArticleAmerican journal of physiology. Lung cellular and molecular physiology2025

Targeting type-2 inflammation in pulmonary hypertension: lessons from a novel model.

Navneet Singh, William M Oldham

Abstract readComment
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of physiology. Lung cellular and molecular physiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Navneet SinghDivision of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, The Warren Alpert School of Medicine, Brown University, Providence, Rhode Island, United States.
William M OldhamDivision of Pulmonary and Critical Care Medicine, Department of Medicine, Harvard Medical School, Boston, Massachusetts, United States.ORCID 0000-0003-3029-4866

Funding

Role of lactate transporters in pulmonary fibrosisR01HL167718 · NHLBI · RHODE ISLAND HOSPITAL · PI William Michael Oldham · 2023 to 2026
$3.4M
HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI) R01HL167718NHLBI NIH HHS R01 HL167718
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Fra-2pulmonary fibrosispulmonary hypertensiontype 2 inflammation

Identifiers

PMID40192583
PMCPMC12100054

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.